FAT1 and head and neck squamous cell carcinoma: Studies have confirmed that FAT1 mutations are highly abundant in cisplatin responders in HNSCC patients, and the gene has been found to have potential targetable changes in 15% of HNSCC patients, which is great news for targeted immunotherapy86.